The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
The Tubulin Inhibitor VERU-111 in Combination With Vemurafenib Provides an Effective Treatment of Vemurafenib-Resistant A375 Melanoma.
复制标题
DOI：
10.3389/fphar.2021.637098
复制
发表时间：
2021
影响因子：
5.6
通讯作者：
Li W
中科院分区：
文献类型：
--
作者：
Cui H;Wang Q;Miller DD;Li W
Melanoma is one of the deadliest skin cancers having a five-year survival rate around 15–20%. An overactivated MAPK/AKT pathway is well-established in BRAF mutant melanoma. Vemurafenib (Vem) was the first FDA-approved BRAF inhibitor and gained great clinical success in treating late-stage melanoma. However, most patients develop acquired resistance to Vem within 6–9 months. Therefore, developing a new treatment strategy to overcome Vem-resistance is highly significant. Our previous study reported that the combination of a tubulin inhibitor ABI-274 with Vem showed a significant synergistic effect to sensitize Vem-resistant melanoma both in vitro and in vivo. In the present study, we unveiled that VERU-111, an orally bioavailable inhibitor of α and β tubulin that is under clinical development, is highly potent against Vem-resistant melanoma cells. The combination of Vem and VERU-111 resulted in a dramatically enhanced inhibitory effect on cancer cells in vitro and Vem-resistant melanoma tumor growth in vivo compared with single-agent treatment. Further molecular signaling analyses demonstrated that in addition to ERK/AKT pathway, Skp2 E3 ligase also plays a critical role in Vem-resistant mechanisms. Knockout of Skp2 diminished oncogene AKT expression and contributed to the synergistic inhibitory effect of Vem and VERU-111. Our results indicate a treatment combination of VERU-111 and Vem holds a great promise to overcome Vem-resistance for melanoma patients harboring BRAF (V600E) mutation.
登录
查看更多内容
影响因子：
11.2
作者：
Díaz-Martínez M;Benito-Jardón L;Alonso L;Koetz-Ploch L;Hernando E;Teixidó J
通讯作者：
Teixidó J
MCF-7 和 MDA-MB-231 细胞对姜黄素细胞毒性作用的不同敏感性与 PI3K/Akt-SKP2-Cip/Kips 通路相关
影响因子：
5.8
作者：
Jia T;Zhang L;Duan Y;Zhang M;Wang G;Zhang J;Zhao Z
通讯作者：
Zhao Z
影响因子：
7.3
作者：
Clement E;Inuzuka H;Nihira NT;Wei W;Toker A
通讯作者：
Toker A
影响因子：
5.7
作者：
Deng, Shanshan;Krutilina, Raisa I.;Li, Wei
通讯作者：
Li, Wei
影响因子：
64.8
作者：
Boussemart, Lise;Malka-Mahieu, Helene;Vagner, Stephan
通讯作者：
Vagner, Stephan